H. Yue

发表

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.

C. Regillo, T. Ianchulev, David M. Brown, 2008, American journal of ophthalmology.

Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.

A. Hauschild, S. Arron, C. Rudin, 2015, Journal of the American Academy of Dermatology.

Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease.

A. Hauschild, D. Schadendorf, R. Dummer, 2014, European journal of cancer.

SNPs and Mutations in C1GALT1C1 Gene and the Susceptibility of Henoch Schonlein Purpura in a Chinese Population

Hongwei Wang, Hongtao Zhao, H. Yue, 2015 .

The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time.

P. Merkel, J. Stone, P. Bekker, 2022, Seminars in Arthritis & Rheumatism.

Efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update.

A. Hauschild, J. Hainsworth, L. Dirix, 2012 .

Metastatic basal cell carcinoma : Prognosis dependent on anatomic site and spread of disease qq

A. Hauschild, D. Schadendorf, R. Dummer, 2014 .

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

M. Brose, S. Sherman, L. Wirth, 2016, The Lancet. Oncology.

Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors

R. Salgia, P. LoRusso, Yoon-Koo Kang, 2020, Molecular Cancer Therapeutics.

First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

G. Demetri, P. Sharma, A. Tolcher, 2021, Clinical Cancer Research.

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.

J. Nemunaitis, R. Heist, K. Kelly, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma.

D. Schadendorf, B. Dréno, N. Basset-Seguin, 2014, The oncologist.

Metastatic basal cell carcinoma: Differences in survival by site of spread.

A. Hauschild, J. Hou, H. Yue, 2012 .

Melanoma and immunotherapy bridge 2015

Andrew J. Park, Ludmila V. Danilova, David C. Smith, 2016, Journal of Translational Medicine.

Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib

P. Hegde, P. Ascierto, J. Larkin, 2017, Clinical Cancer Research.

Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial.

P. Merkel, P. Bekker, D. Jayne, 2023, The Lancet. Rheumatology.

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2.

P. Abraham, H. Yue, L. Wilson, 2010, American journal of ophthalmology.

Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors

G. Sledge, J. Nemunaitis, M. Blaney, 2021, Molecular Cancer Therapeutics.

A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or piatinum-resistant ovarian cancer (OC)

Yulei N. Wang, M. Borad, R. McWilliams, 2014 .

1105PVEMURAFENIB FOR BRAF V600 MUTATED ADVANCED MELANOMA: RESULTS OF TREATMENT BEYOND PROGRESSION.

Y. S. Kim, Su Jin Lee, J. Utikal, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial.

P. Merkel, D. Murrell, P. Bekker, 2023, The Lancet. Rheumatology.

Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC).

Z. Wainberg, L. Naumovski, M. Motwani, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 18-month update of the pivotal ERIVANCE BCC study.

D. Schadendorf, A. Gesierich, C. Garbe, 2013 .

Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors

G. Sledge, J. Nemunaitis, M. Blaney, 2021, Molecular Cancer Therapeutics.

ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev.

M. Blaney, Z. Wainberg, L. Naumovski, 2018 .

MA 02.10 Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC

R. Heist, K. Kelly, D. Camidge, 2017 .

The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial.

F. Pieruzzi, B. Rovin, V. Strand, 2023, The Lancet. Rheumatology.

Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan.

T. Schall, P. Bekker, A. Bruchfeld, 2023, Kidney international reports.